指南与共识血管炎

2021年美国风湿病学会/血管炎基金会大血管血管炎管理指南:巨细胞动脉炎与大动脉炎

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.
指南 / 共识 · Arthritis Care Res (Hoboken) · 2021-07-08

该指南针对巨细胞动脉炎(GCA)和大动脉炎(TAK)的诊断、治疗和管理提出循证推荐与专家指导。共形成GCA 22条推荐和2条未分级立场声明,TAK 20条推荐和1条未分级立场声明,仅2条为强推荐,其余因证据质量低均为条件性推荐。

要点

  • GCA推荐支持使用减少糖皮质激素的免疫抑制剂及影像学识别大血管受累。
  • TAK推荐初始治疗使用非糖皮质激素免疫抑制剂联合糖皮质激素。
  • 多数推荐为条件性,源于多数PICO问题证据质量低。

核心结论

  • 指南为GCA和TAK的诊断评估、药物治疗及手术干预提供循证推荐与专家指导。

研究设计与样本

  • 由美国风湿病学会/血管炎基金会制定,采用PICO格式提出GCA和TAK各27个临床问题,进行系统文献综述,使用GRADE方法评级证据质量,推荐由包括成人和儿童风湿病学家及患者组成的投票小组制定,每条推荐需≥70%共识。

主要发现

  • GCA方面提出22条推荐和2条未分级立场声明,TAK方面提出20条推荐和1条未分级立场声明,覆盖诊断检测(包括影像学)、治疗和手术干预。
  • 仅2条为强推荐,其余推荐因多数PICO问题可用证据质量低而为条件性推荐。

关键数值与推荐

  • GCA推荐包括支持使用减少糖皮质激素的免疫抑制剂以及使用影像学识别大血管受累。
  • TAK推荐包括初始治疗使用非糖皮质激素免疫抑制剂联合糖皮质激素。
  • 每条推荐要求投票小组≥70%共识。

临床怎么用

  • 临床可依据指南对GCA和TAK患者进行诊断策略选择、药物治疗和手术干预决策。

局限性

  • 多数PICO问题可用证据质量低,导致除2条强推荐外其余推荐均为条件性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To provide evidence-based recommendations and expert guidance for the management of giant cell arteritis (GCA) and Takayasu arteritis (TAK) as exemplars of large vessel vasculitis. METHODS: Clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for GCA and TAK (27 for GCA, 27 for TAK). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of the evidence. Recommendations were developed by the Voting Panel, comprising adult and pediatric rheumatologists and patients. Each recommendation required ≥70% consensus among the Voting Panel. RESULTS: We present 22 recommendations and 2 ungraded position statements for GCA, and 20 recommendations and 1 ungraded position statement for TAK. These recommendations and statements address clinical questions relating to the use of diagnostic testing, including imaging, treatments, and surgical interventions in GCA and TAK. Recommendations for GCA include support for the use of glucocorticoid-sparing immunosuppressive agents and the use of imaging to identify large vessel involvement. Recommendations for TAK include the use of nonglucocorticoid immunosuppressive agents with glucocorticoids as initial therapy. There were only 2 strong recommendations; the remaining recommendations were conditional due to the low quality of evidence available for most PICO questions. CONCLUSION: These recommendations provide guidance regarding the evaluation and management of patients with GCA and TAK, including diagnostic strategies, use of pharmacologic agents, and surgical interventions.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Care Res (Hoboken). 2021. PMID: 34235871. doi:10.1002/acr.24632

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。